Edition:
United States

Sarepta Therapeutics Inc (SRPT.O)

SRPT.O on Nasdaq

30.01USD
26 May 2017
Change (% chg)

$-0.84 (-2.72%)
Prev Close
$30.85
Open
$30.76
Day's High
$30.89
Day's Low
$29.40
Volume
2,128,921
Avg. Vol
2,195,785
52-wk High
$63.73
52-wk Low
$14.83

Select another date:

Thu, May 18 2017

Photo

Tourbillon's Karp says Sarepta shares could surge 200 percent

LAS VEGAS Hedge fund manager Jason Karp on Thursday said that shares of Sarepta Therapeutics Inc could climb as much as 200 percent and noted the biotech company could be an attractive takeover candidate.

Tourbillon's Karp says Sarepta shares could surge 200 pct

LAS VEGAS, May 18 Hedge fund manager Jason Karp on Thursday said that shares of Sarepta Therapeutics Inc could climb as much as 200 percent and noted the biotech company could be an attractive takeover candidate.

BRIEF-Sarepta Therapeutics anticipates net revenues for the year to exceed $95 mln

* Sarepta Therapeutics - in Q1, recognized net revenues of $16.3 million in product sales; no revenue was recognized for the same period of 2016

BRIEF-Sarepta appoints Kenneth Fischbeckt to the company’s strategic and scientific advisory board

* Sarepta Therapeutics announces addition of Kenneth Fischbeck, M.D. And matthew wood M.D., Ph.D. to the company’s strategic and scientific advisory board Source text for Eikon: Further company coverage:

BRIEF-Sarepta Therapeutics Q4 non-gaap loss per share $0.71

* Sarepta Therapeutics announces fourth quarter and full-year 2016 financial results and recent corporate developments

BRIEF-Sarepta Therapeutics agrees to sale of priority review voucher for $125 mln

* Sarepta Therapeutics agrees to sale of priority review voucher for $125m

BRIEF-Sarepta Therapeutics enters into license agreement with nationwide children's hospital

* Sarepta Therapeutics enters into license agreement with nationwide children's hospital for GALGT2 gene therapy program Source text for Eikon: Further company coverage:

Select another date:

More From Around the Web